October 2007
Worldwide Biotech;Oct2007, Vol. 19 Issue 10, p7
Trade Publication
The article reports on the license agreement signed by BioLineRx Ltd. with Gene Vector Technologies Ltd. for the development and commercialization of BL-4040, a novel drug for the treatment of acute kidney injury. The said drug is a genetically-engineered version of the major capsid protein VP1 derived from the outer protein shell of the virus SV40. Research found that the drug was effective for the treatment of AKI over a wide dose range and was well-tolerated even at a 1,000 fold excess dose.


Related Articles

  • GSK not to exercise option to license nephropathy drug.  // PharmaWatch: Biotechnology;Mar2008, Vol. 7 Issue 3, p15 

    The article announces the decision of GlaxoSmithKline not to exercise its option to license for further development and commercialization of diabetic nephropathy drug XL784. Exelixis believes that the data of this study is being generated by other compounds to which GSK has an option, though the...

  • BioLineRx Gets BL-4040 Rights; Delves Into Acute Kidney Injury. Boggs, Jennifer // BioWorld International;8/29/2007, Vol. 12 Issue 35, p3 

    The article reports that BioLineRx Ltd. has gained rights to a genetically-engineered version of the capsid protein VPI, a compound believed to have potential in protecting cells following acute kidney injury. The company signed with Gene Vector Technologies Ltd., of Israel, to develop and...

  • Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. BouHamdan, M; Duan, L-X; Pomerantz, R J; Strayer, D S // Gene Therapy;Apr99, Vol. 6 Issue 4, p660 

    Human immunodeficiency virus type I (HIV-1) encodes several proteins that are packaged into virus particles. Integrase (IN) is an essential retroviral enzyme, which has been a target for developing agents to inhibit virus replication. In previous studies, we showed that intracellular expression...

  • BIOLINERX LICENSES PEPTIDE FOR INFLAMMATORY DISEASES.  // Worldwide Biotech;May2007, Vol. 19 Issue 5, p1 

    This article reports on the worldwide exclusive license agreement signed by BioLineRx Ltd., a drug development company in Israel, concerning a peptide for the treatment of inflammatory diseases, with Yissum Research Development Company of the Hebrew University of Jerusalem and Ramot at Tel Aviv...

  • Ikaria, BioLineRx Enter Cardiac Licensing Deal Worth $282.5M. Hollingsworth, Catherine // BioWorld International;7/8/2009, Vol. 14 Issue 27, p2 

    The article reports on a licensing deal signed between Ikaria Holdings Inc. and BioLineRx Ltd. The agreement, estimated to be worth $282.2 million, involved licensing the BL-1040 cardiac remodeling product. It is now in Phase I and II trial. The product itself is created for the purpose of...

  • Cypress Plummets on $365M BioLineRx Schizophrenia Deal. Young, Donna // BioWorld Today;6/22/2010, Vol. 21 Issue 119, p1 

    The article reports on a decline in the shares of Cypress Bioscience Inc. on June 21, 2010 after the company paid BioLineRx Ltd. for development and commercial rights to its antipsychotic drug CYP-1020. According to Cypress Chief Executive Officer (CEO) Jay Kranzler, several of the company's...

  • OTHER NEWS TO NOTE.  // BioWorld Today;10/23/2007, Vol. 18 Issue 206, p2 

    This section offers news briefs on the medical supplies industry. BioLineRX Ltd. presented clinical data on its resorbable implant to treat acute myocardial infarction. Cardium Therapeutics Incorporated's InnerCool Therapies Inc. entered an exclusive license agreement with the University of...

  • BioLineRx Gets Cancer Drug.  // BioWorld Today;12/13/2007, Vol. 18 Issue 241, p7 

    The article reports that BioLineRx Ltd. in Jerusalem has signed a worldwide exclusive license agreement with Yissum and Hadasit to develop and commercialize BL-4060, a small molecule drug candidate for the treatment of cancer. The drug is an analog of the fatty molecule ceramide indicated for...

  • Ikaria, BioLineRx Enter Cardiac Licensing Deal Worth $282.5M. Hollingsworth, Catherine // BioWorld Today;7/7/2009, Vol. 20 Issue 128, p1 

    The article reports on the $282.5 million licensing deal signed by Ikaria Holdings Inc. with Jerusalem-based BioLineRx Ltd. in July 2009. Information on the cardiac remodeling product of BioLineRx called the BL-1040 is offered. Under the deal, BioLineRx will be given upfront and milestone...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics